BD PhaSeal™ Evidence

BD PhaSeal Studies

Studies evaluating fluid leakage during preparation and administration

1. Jorgenson J, Spivey S, Au C et al. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2008; 43(9): 723-727. Click here to read full study


2. Jorgenson J. Leakproof connection integrity test for devices intended for handling hazardous drugs. (Presented at ASHP Midyear Clinical Meeting, December 2007.) Click here to view presentation poster


3. Spivey S, Connor T. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003; 38(2): 135-139. Click here to read full study


4. Nygren O, Gustavsson B, Ström L et al. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit. 2002; 4: 739-742. Click here to read full study


5. Gustavsson B. Evaluation of technetium assay for monitoring of occupational exposure to cytotoxic drugs. J Oncol Pharm Pract. 1997; 3:46.
   

Studies evaluating vapor leakage during preparation and administration

1. Jorgenson J, Spivey S, Au C et al. Contamination comparison of transfer devices intended for handling hazardous drugs. Hosp Pharm. 2008; 43(9): 723-727. Click here to read full study


2. Jorgenson J. 2007 Utah protocol update: evaluation of vial transfer devices for containment of hazardous drug vapors. (Presented at ASHP Midyear Clinical Meeting, December 2007.) Click here to view presentation poster

Studies evaluating the impact of PhaSeal on environmental contamination and exposure of personnel

1. McDiarmid M., Oliver M., Rogers B., et al. Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. JOEM. 2010; 52(10): 1028-1034.


2. Nishigaki R, Konno E, Sugiyasu M et al. The usefulness of a closed-system device for the mixing of injections to prevent occupational exposure to anticancer drugs. Journal of Japanese Society of Hospital Pharmacists. 2010; 46(1): 113-117.


3. Sessink P, Connor T, Jorgenson J et al. Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device. J Oncol Pharm Pract. 2010 Feb 15 [Epub ahead of print]. Click here to read abstract


4. Siderov J, Kirsa S, McLauchlan R. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. J Oncol Pharm Pract. 2010; 16: 19-25. Click here to read abstract


5. Yoshida J; Tei G; Mochizuki C et al. Use of a closed-system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg. 2009; 53(2): 153-160. Click here to read full study


6. Nyman H, Jorgenson J, Slawson M. Workplace contamination with antineoplastic agents in a new cancer hospital using a closed-system drug transfer device. Hosp Pharm. 2007; 42(3): 219-225. Click here to read full study


7. Harrison B, Peters B, Bing M. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques. Am J Health Syst Pharm. 2006; 63: 1736-1744. Click here to read abstract


8. Tans B. Comparative contamination study with cyclophosphamide, fluorouracil and ifosfamide: standard versus a proprietary closed-handling system. J Oncol Pharm Pract. 2004; 10(4): 217-223. Click here to read abstract


9. Wick C, Slawson M, Jorgenson J et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health Syst Pharm. 2003; 60: 2314-2320. Click here to read full study


10. Connor T, Anderson R, Sessink P et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an I.V. admixture area. Am J Health Syst Pharm. 2002; 59: 68-72. Click here to read full study


11. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm Pract. 2001; 6: 146-152. Click here to read abstract


12. Nygren O, Kragh E, Lundgren C et al. Investigations of leakage, spill, airborne emission and exposure during preparation and administration of cytotoxic drugs using different preparation techniques. Poster presentation. National Institute for Working Life, Umea, Sweden and Nijmegen, The Netherlands, 1999.


13. Sessink P, Rolf M, Rydén S. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34: 1311-1317. Click here to read full study

Studies evaluating microbiological integrity and its impact on pharmacy cost-savings scenarios

1. McMichael D, Jefferson D, Carey E et al. Utility of the PhaSeal closed system drug transfer device. The American Journal of Pharmacy Benefits. 2011; 3(1): 9-16. Click here to read full study


2. De Prijck, K, D'Haese E, Vandenbroucke J et al. Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Soc Appl Microbiol. 2008; 47: 543-548. Click here to read abstract


3. Vandenbroucke J, Robays H. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. EJHP Practice. 2008; 14(5): 37-42. Click here to read full study

Studies evaluating the impact of PhaSeal on workflow and staffing

1. Landini K. Implementation of a safety device for use in preparing and administering cytotoxic medications in an inpatient setting (P360D). ASHP Abstracts & Program Resources on CD-ROM. ASHP Midyear Clinical Meeting, December 2006. Click here to view presentation poster


2. Miyamatsu H, Sakamoto M, Azuma K et al. Evaluation of operability of the PhaSeal system, a sealed handling device for anticancer agents. Japanese Journal of Pharmaceutical Health Care and Sciences. 2006; 32(12): 1211-1221. Click here to read abstract


3. Poirer S, Jones C, Calvert M. Practical implementation of a closed system (PhaSeal) for the preparation, administration and disposal of cytotoxic drugs in a busy ambulatory cancer centre. J Oncol Pharm Pract. 2004; 10(2): 81.


4. Ferencak A, Kopp M, Hausermann D. Implementation of safer chemotherapy systems utilized in a VA medical center. (Presented at ASHP Midyear Clinical Meeting, December 2000.)

P463  02/12